CD8A and neoplasm: Blocking this pathway prevents macrophage polarization towards an immunosuppressive M2 phenotype and instead promotes an anti-tumor M1 phenotype, which increases CD8+ T cell activity and enhances the response to anti-PD-1 therapy [96].